Sidra Medicine to Appoint New Chief Executive Officer in January 2016


Sidra Medicine is delighted to announce the appointment of Peter Morris, the former CEO of Barts Health NHS Trust in the United Kingdom, as Sidra Medicine’s new Chief Executive Officer starting on the 8th January 2016.

To date, Peter has pursued an impressive leadership career spanning several of the United Kingdom’s foremost academic medical centers and healthcare providers. He will join Sidra Medicine following his most recent role as the Chief Executive Officer of one of London’s leading hospital groups, Barts Health NHS Trust. During his tenure of this high-profile institution, he led the organization through an unprecedented period of growth and redevelopment by opening three new hospitals and centers of excellence in the capital, including The Royal London Hospital and the Barts Heart Centre, which is now one of the world’s leading specialist centers for adult cardiac services.

Sidra Medicine’s leadership are delighted to welcome Peter Morris on board at this important juncture in the history of the project and as the organization looks forward to opening outpatient maternity and pediatric services in 2016. Peter’s vision and leadership, along with his profound commitment to achieving high-quality healthcare provision and gold-standard research, will help to enable Sidra Medicine in realizing its mission to deliver world-class women and children services for Qatar’s growing healthcare economy.

Professor the Lord Darzi of Denham, Vice-Chairperson of Sidra Medicine said, “Peter will bring a wealth of senior experience in leading large projects and the commissioning of brand new hospitals in the UK, to help lead Sidra Medicine to its next exciting chapter and the provision of patient services in 2016.”

Peter Morris said, “It is a great privilege to be appointed as the new CEO of Sidra Medicine; an organization that shares my deep commitment for achieving the very best standards of healthcare provision and research output for the people of Qatar.”

Further to the announcement, Sidra Medicine’s Acting Chief Executive Officer, Timothy Carmack, will resume his senior leadership role as Chief Financial Officer. He will continue to provide instrumental support and guidance across the organization in this capacity. Sidra Medicine’s Board of Governors extends their gratitude for Tim’s valued leadership and support during the preceding months.